[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607986":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":53,"centralContacts":56,"locations":64,"responsibleParty":227,"collaborators":11,"id":229,"slug":230,"hasResults":231,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":11,"eligibilityCriteria":235,"healthyVolunteers":231,"sex":236,"minAge":237,"maxAge":11,"enrollmentInfo":238,"targetDuration":11,"studyType":241,"phases":242,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":67,"whyStopped":11,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":261},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14,17,20,24,28,31],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1A BMS-986506 Monotherapy Escalation","EXPERIMENTAL",null,[13],"Drug: BMS-986506",{"label":15,"type":10,"description":11,"interventionNames":16},"Part 2A BMS-986506 Monotherapy Expansion",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Part 2B BMS-986506 Monotherapy Expansion",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Part 3A BMS-986506 + Pumitamig Combination Dose Escalation",[13,23],"Drug: Pumitamig",{"label":25,"type":10,"description":11,"interventionNames":26},"Part 3B BMS-986506 + Pumitamig + Ipilimumab Combination Dose Escalation",[13,23,27],"Drug: Ipilimumab",{"label":29,"type":10,"description":11,"interventionNames":30},"Part 4A BMS-986506 + Pumitamig Combination Dose Expansion",[13,23],{"label":32,"type":10,"description":11,"interventionNames":33},"Part 4B BMS-986506 + Pumitamig + Ipilimumab Combination Dose Expansion",[13,23,27],[35,40,47],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"DRUG","BMS-986506","Specified dose on specified days",[9,15,18,21,25,29,32],{"type":36,"name":41,"description":38,"armGroupLabels":42,"otherNames":43},"Pumitamig",[21,25,29,32],[44,45,46],"BMS-986545","BNT327","PM8002",{"type":36,"name":48,"description":38,"armGroupLabels":49,"otherNames":50},"Ipilimumab",[25,32],[51,52],"Yervoy","BMS-734016",[54],{"name":5,"affiliation":5,"role":55},"STUDY_DIRECTOR",[57,62],{"name":58,"role":59,"phone":60,"phoneExt":11,"email":61},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":63,"role":59,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[65,83,96,110,124,138,154,170,185,197,213],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"Dana-Farber Cancer Institute","RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":74,"coordinates":75},"Point",[76,77],-71.05977,42.35843,{"lat":77,"lon":76},[80],{"name":81,"role":59,"phone":82,"phoneExt":11,"email":11},"Stephanie Berg, Site 0006","617-632-4932",{"facility":84,"status":67,"city":85,"state":85,"zip":86,"country":71,"countryCode":72,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":74,"coordinates":88},[89,90],-74.00597,40.71427,{"lat":90,"lon":89},[93],{"name":94,"role":59,"phone":95,"phoneExt":11,"email":11},"Martin Voss, Site 0029","646-888-4721",{"facility":97,"status":67,"city":98,"state":99,"zip":100,"country":71,"countryCode":72,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Fox Chase Cancer Center","Philadelphia","Pennsylvania","19111",{"type":74,"coordinates":102},[103,104],-75.16362,39.95238,{"lat":104,"lon":103},[107],{"name":108,"role":59,"phone":109,"phoneExt":11,"email":11},"Elizabeth Plimack, Site 0002","215-728-3889",{"facility":111,"status":67,"city":112,"state":113,"zip":114,"country":71,"countryCode":72,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":74,"coordinates":116},[117,118],-86.78444,36.16589,{"lat":118,"lon":117},[121],{"name":122,"role":59,"phone":123,"phoneExt":11,"email":11},"Benjamin Garmezy, Site 0026","713-444-7804",{"facility":125,"status":67,"city":126,"state":127,"zip":128,"country":71,"countryCode":72,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"START San Antonio","San Antonio","Texas","78229",{"type":74,"coordinates":130},[131,132],-98.49363,29.42412,{"lat":132,"lon":131},[135],{"name":136,"role":59,"phone":137,"phoneExt":11,"email":11},"Amita Patnaik, Site 0001","210-593-5250",{"facility":139,"status":67,"city":140,"state":141,"zip":142,"country":143,"countryCode":144,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"Arthur J.E. Child Comprehensive Cancer Centre","Calgary","Alberta","T2N 5G2","Canada","CA",{"type":74,"coordinates":146},[147,148],-114.08529,51.05011,{"lat":148,"lon":147},[151],{"name":152,"role":59,"phone":153,"phoneExt":11,"email":11},"Daniel Heng, Site 0021","4035213166",{"facility":155,"status":67,"city":156,"state":157,"zip":158,"country":159,"countryCode":160,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Gustave Roussy","Villejuif","Val-de-Marne","94800","France","FR",{"type":74,"coordinates":162},[163,164],2.35992,48.7939,{"lat":164,"lon":163},[167],{"name":168,"role":59,"phone":169,"phoneExt":11,"email":11},"Christophe Massard, Site 0008","+33142114211",{"facility":171,"status":172,"city":173,"state":11,"zip":174,"country":175,"countryCode":176,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"Local Institution - 0031","NOT_YET_RECRUITING","Roma","00168","Italy","IT",{"type":74,"coordinates":178},[179,180],11.10642,44.99364,{"lat":180,"lon":179},[183],{"name":184,"role":59,"phone":11,"phoneExt":11,"email":11},"Site 0031",{"facility":186,"status":172,"city":187,"state":11,"zip":188,"country":175,"countryCode":176,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"Local Institution - 0033","Verona","37134",{"type":74,"coordinates":190},[191,192],10.9938,45.43854,{"lat":192,"lon":191},[195],{"name":196,"role":59,"phone":11,"phoneExt":11,"email":11},"Site 0033",{"facility":198,"status":67,"city":199,"state":200,"zip":201,"country":202,"countryCode":203,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"Hospital Universitario Reina Sofia","Córdoba","Andalusia","14004","Spain","ES",{"type":74,"coordinates":205},[206,207],-4.77275,37.89155,{"lat":207,"lon":206},[210],{"name":211,"role":59,"phone":212,"phoneExt":11,"email":11},"MARIA JOSE MENDEZ VIDAL, Site 0015","+34957011448",{"facility":214,"status":67,"city":215,"state":216,"zip":217,"country":202,"countryCode":203,"cosmosGeoPoint":218,"geoPoint":222,"contacts":223},"Hospital Universitari Vall d'Hebron","Barcelona","Barcelona [Barcelona]","08035",{"type":74,"coordinates":219},[220,221],2.15899,41.38879,{"lat":221,"lon":220},[224],{"name":225,"role":59,"phone":226,"phoneExt":11,"email":11},"Cristina Suarez Rodriguez, Site 0018","349327460004350",{"type":228,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100607986","phase-1-a-first-in-human-study-of-bms-986506-in-participants-with-advanced-clear-cell-renal-cell-carcinoma-ccrcc-100607986",false,"NCT07195682","A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)","A Phase 1\u002F1b Open-label, Multi-center Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)","Inclusion Criteria\n\n* Participants must have histologically confirmed diagnosis of locally advanced or metastatic ccRCC.\n* For part 1: Participants must have already had at least two different treatment plans in the past, including immunotherapy and a targeted therapy.\n* For part 2: Participants must have had at least one standard treatment plan that included both a PD-1\u002FL1 inhibitor and a VEGF-TKI (either together or one after the other).\n* Part 3: Participants must have had at least 1 standard treatment regimen (including a PD-1\u002FL1 checkpoint inhibitor and\u002For a VEGF-TKI).\n* Part 4: Participants must not have received prior systemic therapy for metastatic RCC, but may have received prior adjuvant therapy for completely resected RCC with PD-1 inhibitor if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy.\n* Eastern Cooperative Oncology Group performance status of 0 to 1.\n\nExclusion Criteria\n\n* Inability to administer and\u002For tolerate oral medication without chewing, breaking, crushing, or otherwise altering the product dosage form.\n* Part 2A: Participants who have received more than 3 prior systemic regimens for locally advanced or metastatic ccRCC including prior treatment with HIF2a inhibitors.\n* Part 2A and Part 4: Participants who have received prior treatment with belzutifan (or another HIF2a inhibitor).\n* Part 3B and Part 4B: Participants who have received prior ipilimumab (or another anti-CTLA-4 containing antibody).\n* Participants who have hypoxia as defined by a pulse oximeter reading \\\u003C 92% at rest or requires intermittent or chronic supplemental oxygen.\n* Participants who have received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 28 days prior to the first dose of study intervention.\n* Part 3 and Part 4: Participants with a history of Grade ≥3 immune-mediated AEs leading to discontinuation of prior immunotherapy.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years",{"count":239,"type":240},281,"ESTIMATED","INTERVENTIONAL",[243],"PHASE1","This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone or in combination by participants with ccRCC.",[246],"Renal Cell Carcinoma",[248,249,250,251],"Metastatic clear cell renal cell carcinoma","Advanced clear cell renal cell carcinoma","ccRCC","Kidney cancer","2026-08-07",{"date":254,"type":255},"2026-08-11","ACTUAL",{"date":257,"type":255},"2026-01-15",{"date":259,"type":240},"2031-04-03",{"name":5,"class":6},11]